These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 603749)

  • 1. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature.
    Mosher DB; Parrish JA; Fitzpatrick TB
    Br J Dermatol; 1977 Dec; 97(6):669-79. PubMed ID: 603749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin.
    Kasraee B; Fallahi MR; Ardekani GS; Ebrahimi S; Doroudchi G; Omrani GR; Handjani F; Amini M; Tanideh N; Haddadi M; Nikbakhsh M; Jahanbani S; Tran C; Sorg O; Saurat JH
    Exp Dermatol; 2006 Jul; 15(7):509-14. PubMed ID: 16761959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depigmentation therapies for normal skin in vitiligo universalis.
    AlGhamdi KM; Kumar A
    J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):749-57. PubMed ID: 21054565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation.
    Hariharan V; Klarquist J; Reust MJ; Koshoffer A; McKee MD; Boissy RE; Le Poole IC
    J Invest Dermatol; 2010 Jan; 130(1):211-20. PubMed ID: 19657355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.
    Webb KC; Eby JM; Hariharan V; Hernandez C; Luiten RM; Le Poole IC
    Exp Dermatol; 2014 Aug; 23(8):529-33. PubMed ID: 24840876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid repigmentation after depigmentation therapy: vitiligo treated with monobenzyl ether of hydroquinone.
    Oakley AM
    Australas J Dermatol; 1996 May; 37(2):96-8. PubMed ID: 8687336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depigmentation Therapies for Vitiligo.
    Grimes PE; Nashawati R
    Dermatol Clin; 2017 Apr; 35(2):219-227. PubMed ID: 28317530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of depigmenting chemical agents on hair and skin color in yellow (pheomelanic) and black (eumelanic) mice.
    Quevedo WC; Holstein TJ; Dyckman J; Nordlund JJ
    Pigment Cell Res; 1990; 3(2):71-9. PubMed ID: 2385568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser.
    Njoo MD; Vodegel RM; Westerhof W
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):760-9. PubMed ID: 10775851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of Monobenzone-Induced Vitiligo Mouse Model by the Addition of Chronic Stress.
    Dong J; Lai Y; Zhang X; Yue Y; Zhong H; Shang J
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Monobenzyl ether of hydroquinone on 3T3 mouse fibroblast viability and ultrastructure.
    Erdoğan A; Mutlu HS; Doğan S; Kotil T
    Ultrastruct Pathol; 2021 Nov; 45(6):384-390. PubMed ID: 34875974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.
    Bonchak JG; Eby JM; Willenborg KA; Chrobak D; Henning SW; Krzywiec A; Johnson SL; Le Poole IC
    Arch Biochem Biophys; 2014 Dec; 563():71-8. PubMed ID: 25132642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acquired leukomelanoderma caused by topical depigmenting agents].
    Grojean MF; Thivolet J; Perrot H
    Ann Dermatol Venereol; 1982; 109(8):641-7. PubMed ID: 7187189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical induced pathognomonic features observed in human vitiligo are mediated through miR-2909 RNomics pathway.
    Kaushik H; Kaul D; Kumaran MS; Parsad D
    J Dermatol Sci; 2020 Nov; 100(2):92-98. PubMed ID: 33039241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depigmentation therapies in vitiligo.
    Gupta D; Kumari R; Thappa DM
    Indian J Dermatol Venereol Leprol; 2012; 78(1):49-58. PubMed ID: 22199060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatitis produced by applications of monobenzone in patients with active vitiligo.
    Nordlund JJ; Forget B; Kirkwood J; Lerner AB
    Arch Dermatol; 1985 Sep; 121(9):1141-4. PubMed ID: 2931053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Irreversible toxic depigmentation. Observations following use of hydroquinonemonobenzylether-containing skin bleaching preparations].
    Heilgemeir GP; Balda BR
    MMW Munch Med Wochenschr; 1981 Jan; 123(2):47-8. PubMed ID: 6782448
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of vitiligo].
    Frenk E
    Hautarzt; 1986 Jan; 37(1):1-5. PubMed ID: 3949507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and experimental treatments of vitiligo and other hypomelanoses.
    Lotti T; Prignano F; Buggiani G
    Dermatol Clin; 2007 Jul; 25(3):393-400, ix. PubMed ID: 17662905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depigmentation therapy for vitiligo in patients with Fitzpatrick skin type VI.
    Black W; Russell N; Cohen G
    Cutis; 2012 Feb; 89(2):57-60. PubMed ID: 22474725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.